March 2021

In the next issue of Pharma Technology Focus, we take a look at the controversial acquisition of the ‘HeLa’ cell line from Henrietta Lacks that has been a mainstay of the biotechnology industry for decades, and consult with legal experts to learn more about skinny labelling and the fine print of generics. 

Also, we track the development of antibody-drug conjugates, explore the often-overlooked gastrointestinal symptoms associated with Covid-19, and learn how Ambien is being used to help unlock the mysteries of akinetic mutism.

Plus, we speak to Fusion about the future of radiopharmaceuticals in the fight against cancer, examine innovation in the HIV drug market as the competition for market dominance heats up, and investigate the issue of excluding pre-menopausal women from breast cancer trials. 


Editor | Eloise McLennan

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Natalie Healey, Abi Millar, Chloe Kent
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West


Sales Manager | Nimai Amin

+44 (0) 207 936 6453


For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.